Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Financing Activities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash from Financing Activities for 11 consecutive years, with $17.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities changed N/A to $17.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $78.7 million, a 7551.46% increase, with the full-year FY2024 number at $56.0 million, down 52.54% from a year prior.
  • Cash from Financing Activities was $17.2 million for Q3 2025 at Editas Medicine, up from $7.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $261.5 million in Q1 2021 to a low of -$1.4 million in Q1 2025.
  • A 5-year average of $30.0 million and a median of $838000.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 31923.16% in 2023, then plummeted 848.44% in 2025.
  • Editas Medicine's Cash from Financing Activities stood at $1.1 million in 2021, then plummeted by 41.44% to $619000.0 in 2022, then decreased by 16.96% to $514000.0 in 2023, then surged by 10700.19% to $55.5 million in 2024, then plummeted by 69.07% to $17.2 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Cash from Financing Activities are $17.2 million (Q3 2025), $7.4 million (Q2 2025), and -$1.4 million (Q1 2025).